I
| Evidence from at least one large randomized controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomized trials without heterogeneity |
II
| Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity |
III
| Prospective cohort studies |
IV
| Retrospective cohort studies or case–control studies |
V
| Studies without control group, case reports, expert opinions |
Grades of recommendations
|
A
| Strong evidence for efficacy with a substantial clinical benefit, strongly recommended |
B
| Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended |
C
| Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc), optional |
D
| Moderate evidence against efficacy or for adverse outcome, generally not recommended |
E
| Strong evidence against efficacy or for adverse outcome, never recommended |